UBIQUITIN PROTEASOME PATHWAY

PROGRAM PUBLICATIONS


1. Amit, I., R. Wides, and Y. Yarden, Evolvable signaling networks of receptor tyrosine kinases: relevance of robustness to malignancy and to cancer therapy. Mol Syst Biol, 2007. 3: p. 151.

2. Moussaieff, A., et al., Incensole acetate, a novel anti-inflammatory compound isolated from Boswellia resin, inhibits nuclear factor-kappa B activation. Mol Pharmacol, 2007. 72(6): p. 1657-64.

3. Shabek, N., K. Iwai, and A. Ciechanover, Ubiquitin is degraded by the ubiquitin system as a monomer and as part of its conjugated target. Biochem Biophys Res Commun, 2007. 363(2): p. 425-31.

4. Melino, G., et al., Itch: a HECT-type E3 ligase regulating immunity, skin and cancer. Cell Death Differ, 2008. 15(7): p. 1103-12.

5. Minsky, N., et al., Monoubiquitinated H2B is associated with the transcribed region of highly expressed genes in human cells. Nat Cell Biol, 2008. 10(4): p. 483-8.

6. Mosesson, Y., G.B. Mills, and Y. Yarden, Derailed endocytosis: an emerging feature of cancer. Nat Rev Cancer, 2008. 8(11): p. 835-50.

7. Ofir-Rosenfeld, Y., et al., Mdm2 regulates p53 mRNA translation through inhibitory interactions with ribosomal protein L26. Mol Cell, 2008. 32(2): p. 180-9.

8. Sadeh, R., et al., The N-terminal domain of MyoD is necessary and sufficient for its nuclear localization-dependent degradation by the ubiquitin system. Proc Natl Acad Sci U S A, 2008. 105(41): p. 15690-5.

9. Shema, E., et al., The histone H2B-specific ubiquitin ligase RNF20/hBRE1 acts as a putative tumor suppressor through selective regulation of gene expression. Genes Dev, 2008. 22(19): p. 2664-76.

10. Vainer, G.W., E. Pikarsky, and Y. Ben-Neriah, Contradictory functions of NF-kappaB in liver physiology and cancer. Cancer Lett, 2008. 267(2): p. 182-8.

11. Amir, S., et al., SEPT9_v1 up-regulates hypoxia-inducible factor 1 by preventing its RACK1-mediated degradation. J Biol Chem, 2009. 284(17): p. 11142-51.

12. Aylon, Y., et al., Silencing of the Lats2 tumor suppressor overrides a p53-dependent oncogenic stress checkpoint and enables mutant H-Ras-driven cell transformation. Oncogene, 2009. 28(50): p. 4469-79.

13. Ben-Kasus, T., et al., Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: relevance of receptor endocytosis. Proc Natl Acad Sci U S A, 2009. 106(9): p. 3294-9.

14. Ciechanover, A., Tracing the history of the ubiquitin proteolytic system: the pioneering article. Biochem Biophys Res Commun, 2009. 387(1): p. 1-10.

15. Kravtsova-Ivantsiv, Y., S. Cohen, and A. Ciechanover, Modification by single ubiquitin moieties rather than polyubiquitination is sufficient for proteasomal processing of the p105 NF-kappaB precursor. Mol Cell, 2009. 33(4): p. 496-504.

16. Mosesson, Y., et al., Monoubiquitinylation regulates endosomal localization of Lst2, a negative regulator of EGF receptor signaling. Dev Cell, 2009. 16(5): p. 687-98.

17. Tarcic, G., et al., An unbiased screen identifies DEP-1 tumor suppressor as a phosphatase controlling EGFR endocytosis. Curr Biol, 2009. 19(21): p. 1788-98.

18. Amir, S., M. Golan, and N. Mabjeesh, Silencing SEPT9_v1 inhibits tumor growth and angiogenesis in preparation, 2010.

19. Amir, S., M. Golan, and N.J. Mabjeesh, Targeted knockdown of SEPT9_v1 inhibits tumor growth and angiogenesis of human prostate cancer cells concomitant with disruption of hypoxia-inducible factor-1 pathway. Mol Cancer Res, 2010. 8(5): p. 643-52.

20. Cohen, S., et al., A20 and ABIN-1 regulate processing of the p105 precursor - a novel mechanism for controlling NF-kB activity. submitted, 2010.

21. Elyada, E., et al., Intestinal CKIa ablation reveals a carcinogenesis barrier mechanism: Wnt hypersignaling coupled to inflammatory and DNA damage responses. submitted, 2010.

22. Gielchinsky, Y., et al., Pregnancy restores the regenerative capacity of the aged liver via activation of an mTOR-controlled hyperplasia/hypertrophy switch. submitted, 2010.

23. Gluschneider, U., et al., β-TrCP inhibition reduces prostate cancer cell growth via upregulation of the Arylhydrocarbon receptor. submitted, 2010.

24. Kanarek, N., et al., Spermatogenesis rescue in a mouse deficient for the ubiquitin ligase SCFβ-TrCP by single substrate depletion. submitted, 2010.

25. Kanarek, N., et al., Ubiquitination and degradation of the inhibitors of NF-kappaB. Cold Spring Harb Perspect Biol, 2010. 2(2): p. a000166.

26. Lindzen, M., et al., Tailored cancer immunotherapy using combinations of chemotherapy and a mixture of antibodies against EGF-receptor ligands. Proc Natl Acad Sci U S A, 2010. 107(28): p. 12559-63.

27. Manisterski, M., et al., PTHrP is induced by hypoxia via the HIF-2 pathway. in preparation, 2010.

28. Moyal, L., et al., ATM-dependent monoubiquitination of histone H2B at DNA double strand breaks is required for timely damage repair. submitted, 2010.

29. Pines, G., W.J. Kostler, and Y. Yarden, Oncogenic mutant forms of EGFR: lessons in signal transduction and targets for cancer therapy. FEBS Lett, 2010. 584(12): p. 2699-706.

30. Stambolsky, P., et al., Modulation of the vitamin D3 response by cancer-associated mutant p53. Cancer Cell, 2010. 17(3): p. 273-85.

31. Witsch, E., M. Sela, and Y. Yarden, Roles for growth factors in cancer progression. Physiology (Bethesda), 2010. 25(2): p. 85-101.

© 2009 DR. MIRIAM AND SHELDON G. ADELSON MEDICAL RESEARCH FOUNDATION
ALL RIGHTS RESERVED